These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24596374)

  • 21. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
    Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A
    Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
    von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
    Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
    Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y; Booser DJ; Sneige N
    Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: a multicenter, randomized, phase II study comparing 2 administration regimens.
    Goldstein LJ; Gurtler J; Del Prete SA; Tjulandin S; Semiglazov VF; Bayever E; Michiels B
    Clin Breast Cancer; 2014 Dec; 14(6):396-404. PubMed ID: 25239225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determining which patients require irradiation of the supraclavicular nodal area after surgery for N1 breast cancer.
    Yu JI; Park W; Huh SJ; Choi DH; Lim YH; Ahn JS; Yang JH; Nam SJ
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1135-41. PubMed ID: 20231065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity.
    Toulmonde M; Madranges N; Brouste V; Donamaria C; MacGrogan G; Durand M; Bonnefoi H; Mauriac L; Debled M
    Breast Cancer Res Treat; 2012 Jul; 134(1):325-32. PubMed ID: 22531859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gallbladder metastases of breast cancer: from clinical-pathological patterns to diagnostic and therapeutic strategy.
    Di Vita M; Zanghì A; Lanzafame S; Cavallaro A; Piccolo G; Berretta M; Grosso G; Cappellani A
    Clin Ter; 2011; 162(5):451-6. PubMed ID: 22041804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence.
    Marques AR; Teixeira E; Diamond J; Correia H; Santos S; Neto L; Ribeiro M; Miranda A; Passos-Coelho JL
    Breast Cancer Res Treat; 2009 Mar; 114(2):223-32. PubMed ID: 18409061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
    White R; Dinneen T; Makris A
    Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The outcome effect of double-hormonal therapy in premenopausal breast cancer patients with high nodal-status: Result of a prospective randomized trial.
    Uslu A; Zengel B; Akpinar G; Postaci H; Yetis H; Corumlu B; Kebapci E; Aykas A
    Indian J Cancer; 2014; 51(4):582-6. PubMed ID: 26842203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer.
    Lanigan F; McKiernan E; Brennan DJ; Hegarty S; Millikan RC; McBryan J; Jirstrom K; Landberg G; Martin F; Duffy MJ; Gallagher WM
    Int J Cancer; 2009 May; 124(9):2088-97. PubMed ID: 19142967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma.
    Adachi Y; Ishiguro J; Kotani H; Hisada T; Ichikawa M; Gondo N; Yoshimura A; Kondo N; Hattori M; Sawaki M; Fujita T; Kikumori T; Yatabe Y; Kodera Y; Iwata H
    BMC Cancer; 2016 Mar; 16():248. PubMed ID: 27015895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lobular Breast Cancer and Abdominal Metastases: A Retrospective Review and Impact on Survival.
    Winn JS; Baker MG; Fanous IS; Slack-Davis JK; Atkins KA; Dillon PM
    Oncology; 2016; 91(3):135-42. PubMed ID: 27355204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer.
    Lavrenkov K; Man S; Geffen DB; Cohen Y
    Isr Med Assoc J; 2002 Mar; 4(3):176-7. PubMed ID: 11908256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bevacizumab in advanced breast cancer: a new model for the assessment of activity in non-first-line treatment regimens.
    Haba-Rodríguez Jde L; González A; Cortés J; Rodríguez-Lescure Á; Sánchez A; Pulido G; Cortijo A; Guirado M; Torrejón D; Alba E
    Anticancer Drugs; 2013 Oct; 24(9):975-9. PubMed ID: 23863615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process.
    Vincent-Salomon A; Jouve M; Genin P; Fréneaux P; Sigal-Zafrani B; Caly M; Beuzeboc P; Pouillart P; Sastre-Garau X
    Cancer; 2002 Apr; 94(8):2169-73. PubMed ID: 12001113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases.
    Cutuli B; De Lafontan B; Kirova Y; Auvray H; Tallet A; Avigdor S; Brunaud C; Delva C
    Radiat Oncol; 2015 May; 10():110. PubMed ID: 25944033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.